https://www.selleckchem.com/products/cm-4620.html e. surgeons and oncologists) and general practitioners. The primary outcome is health-related quality of life as measured by the Functional Assessment of Cancer Therapy-Breast Cancer. Secondary outcomes include patient experience, acceptance, and satisfaction of care; dietary, physical activity, and sedentary behaviours; financial toxicity; adherence; health resource utilisation; and adverse events. The trial is designed to identify the barriers to implementing a shared-care model for breast cancer survivors following treatment. Results of this study will inform a definitive trial testing the effects of shared-care model on health-related quality of life of breast cancer survivors, as well as its ability to alleviate the growing demands on the healthcare system. Australia and New Zealand Clinical Trials Registry ACTRN12619001594112 . Registered on 19 November 2019. Australia and New Zealand Clinical Trials Registry ACTRN12619001594112 . Registered on 19 November 2019. There is an emerging literature on the impact of correctional substance abuse treatment (SAT) on reoffending for people in prison with substance misuse issues. This study estimates a pathway effect for people in prison receiving multiple component treatments for an alcohol use disorder (AUD) to reduce reoffending by applying treatment effect estimation techniques for observational studies. Treatment groups comprised pharmacological treatments, psychosocial interventions (PSIs) and interventions that incorporate Risk Need Responsivity (RNR) programming. RNR compliant treatment matches treatment dose to the risk of reoffending, targets criminogenic need and is tailored to a person's learning style. Multiple treatment effect estimators are provided for people in prison diagnosed with an AUD in England when compared to a derived control group for Pharmacological treatment only; RNR compliant treatment and PSIs. The outcomes for RNR compliant treatment sugge